Introduction
============

Cholangiocarcinoma is the second most common type of primary liver cancer worldwide, following hepatocellular carcinoma (HCC) ([@b1-ol-0-0-5991]). A higher number of mortalities are ascribed to cholangiocarcinoma, compared with HCC, in England and Wales since mid-1990 ([@b1-ol-0-0-5991],[@b2-ol-0-0-5991]). Cholangiocarcinoma is rare in the majority of Western countries, and the rate of incidence ranges from 0.35/100,000 in Canada to 3.36/100,000 in Italy ([@b2-ol-0-0-5991]). Conversely, the reported incidences are significantly higher in certain areas of Asia, including \~5.7--85.0/100,000 in Thailand, \~7.45--7.55/100,000 in China, \~7.10--8.75/100,000 in Korea and \~3.05--3.40/100,000 in Japan ([@b2-ol-0-0-5991]). In Taiwan, a modest incidence of cholangiocarcinoma at 4.7/100,000 has been reported ([@b2-ol-0-0-5991]).

Cholangiocarcinoma emerges from the dysregulated proliferation of bile duct epithelial cells, known as cholangiocytes, and is notorious for its poor prognosis and response to chemotherapy ([@b3-ol-0-0-5991]). Clinically, cholangiocarcinoma is comprised of a group of tumors with markedly heterogeneous morphology, histology and clinical presentation ([@b3-ol-0-0-5991]). Cholangiocarcinoma may be classified as intrahepatic and extrahepatic types ([@b1-ol-0-0-5991]--[@b3-ol-0-0-5991]). The extrahepatic tumor is further classified into perihilar (Klatskin tumor) and distal forms ([@b3-ol-0-0-5991]). However, in certain cancer registries and epidemiological studies, perihilar cholangiocarcinoma has been considered as an intrahepatic tumor ([@b4-ol-0-0-5991]).

The etiology of cholangiocarcinoma remains largely unknown ([@b4-ol-0-0-5991]). Risk factors for cholangiocarcinoma include old age, primary sclerosing cholangitis, biliary tree stones and structural anomalies of bile ducts and liver flukes; however, combined, they account for \<30% of cholangiocarcinoma cases ([@b1-ol-0-0-5991]). Numerous molecular changes have been identified in cholangiocarcinoma, including the inactivation of tumor suppressor genes \[tumor protein 53, anaphase-promoting complex, mothers against decapentaplegic homolog 4 (*SMAD4*) and *cyclin dependent kinase inhibitor 2A*\], somatic mutations or the upregulation of oncogenes \[e.g. Kirsten rat sarcoma (*KRas), c-Myc* and human epidermal growth factor receptor 2 *(ERBB2)*\], and other chromosomal anomalies ([@b2-ol-0-0-5991]).

Surgical resection is applicable to \<40% of all intrahepatic cholangiocarcinoma cases ([@b1-ol-0-0-5991],[@b5-ol-0-0-5991]). Transcatheter arterial chemoembolization (TACE), radiofrequency ablation and combination chemotherapy (gemcitabine + cisplatin), have been used for the treatment of unresectable and recurrent cholangiocarcinoma ([@b1-ol-0-0-5991],[@b2-ol-0-0-5991]). A number of clinicopathological and genetic parameters have been identified as poor prognostic factors following surgical resection, including lymph node metastasis ([@b1-ol-0-0-5991]), positive resection margin ([@b6-ol-0-0-5991]), perineural invasion ([@b7-ol-0-0-5991]) and *KRas* mutations ([@b8-ol-0-0-5991]). No cancer staging systems and standard of care guidelines have been globally accepted ([@b9-ol-0-0-5991],[@b10-ol-0-0-5991]). However, four tumor characteristics, including vascular invasion, tumor number, lymph node metastasis and distant metastasis, are the major determinants in two staging systems developed independently in Japan and the United States to address the post-resection survival of intrahepatic cholangiocarcinoma ([@b9-ol-0-0-5991],[@b10-ol-0-0-5991]). Three staging systems are available for perihilar cholangiocarcinoma, including the American Joint Committee on Cancer Tumor-Node-Metastasis (TNM) system ([@b11-ol-0-0-5991]), the Bismuth-Corlette staging system ([@b12-ol-0-0-5991]) and the Blumgart modifications ([@b13-ol-0-0-5991]). All of these staging systems correlated poorly with post-resection survival in an earlier validation study ([@b14-ol-0-0-5991]).

Previously, through the use of the genome-wide association method followed by prospective validation, it was revealed that the germline genotypes of polypeptide N-acetylgalactosaminyltransferase 14 (*GALNT14*) may serve as response predictors for chemotherapy in HCC ([@b15-ol-0-0-5991]). A leading single nucleotide polymorphism, rs9679162, was identified to be associated with chemotherapy response, time-to-tumor progression and overall survival in a previous study of patients with HCC at Barcelona Clinic Liver Cancer (BCLC) Stage C ([@b16-ol-0-0-5991],[@b17-ol-0-0-5991]). The genotypes were also identified to correlate with the therapeutic response in TACE-treated patients with HCC at BCLC Stage B ([@b18-ol-0-0-5991]). It was revealed that the gene product of *GALNT14* was an enzyme catalyzing O-glycosylation of numerous proteins, including the death receptors (DRs) 4 and 5 ([@b19-ol-0-0-5991]). O-glycosylation of DR 4/5 increased their sensitivity to extrinsic apoptotic signals ([@b19-ol-0-0-5991]). Furthermore, germline mutations in *GALNT14* were associated with an increased risk of hereditary neuroblastoma ([@b20-ol-0-0-5991]) and *GALNT14* was recently identified as an embryonic lethal gene based on studies in consanguineous families ([@b21-ol-0-0-5991]). Therefore, the association between the *GALNT14* genotype and tumor behavior may not be restricted to HCC. The present study examined the association between the prognosis of patients with resected cholangiocarcinoma and the *GALNT14* genotype.

Materials and methods
=====================

### Patients

Under approval of the Institutional Review Board of Chang Gung Memorial Hospital (Taoyuan, Taiwan ROC), surgical tissue samples from 112 patients with cholangiocarcinoma, resected between January 1999-December 2008, were retrieved from the hospital\'s tissue bank, without any specific selection criteria. Written informed consent was obtained from all patients enrolled in the present study. Patients\' clinical data were subsequently collected (see [Table I](#tI-ol-0-0-5991){ref-type="table"}), including age, sex, hepatitis B virus (HBV) surface antigen (HBsAg), anti-hepatitis C antibody (anti-HCV), cirrhosis, Eastern Co-operative Oncology Group performance status, biliary tree stones, cholangitis, tumor characteristics (location, invasion to vessels, perineural invasion, periductal invasion, lymph node metastasis, tumor number and size), histology, extrahepatobiliary invasion, resection margin and the extent of surgical resection. Pre-surgery biochemical data was collected, including on carcinoembryonic antigen (CEA), carbohydrate antigen 19--9 (CA-19-9), bilirubin, aspartate transaminase (AST) and alanine transaminase (ALT).

### GALNT14 genotyping

*GALNT14* genotyping was performed on thawed surgical tissue samples, which were freshly cryopreserved at −70°C immediately following surgery. DNA was extracted from the tissues using QIAamp DNA Mini and Blood Mini kits (Qiagen GmbH, Hilden, Germany) following the manufacturers\' protocol. Polymerase chain reactions were performed using a pair of primers (5′-TCACGAGGCCAACATTCTAG-3′ and 5′-TTAGATTCTGCATGGCTCAC-3′) to amplify the DNA fragment containing *GALNT14*-rs9679162 (95°C, 1 min; 55°C, 1 min; 72°C, 1 min; 30 cycles), followed by direct sequencing using the conventional Sanger sequencing method ([@b22-ol-0-0-5991]). To ensure the accuracy of genotyping for each sample, polymerase chain reaction was performed two times and bidirectional sequencing was carried out.

### Statistical analysis

Parametric data is presented as mean ± standard deviation. Dichotomous data is presented as percentage. The genotype counts of *GALNT14*-rs9679162 in HapMap Chinese Han Beijing (CHB) and Metropolitan Denver (CHD) cohorts were retrieved from the public domain (<http://hapmap.ncbi.nlm.nih.gov/>). These counts were compared with those obtained from the present study. Associations between the *GALNT14* rs9679162 genotypes and clinical factors were analyzed using univariate and multivariate linear regressions. Genotype distributions were compared using the Cochran-Armitage Trend test or χ^2^ test. Loss of follow up was considered as censored data. Post-resection overall survival was analyzed using log-rank tests, Kaplan-Meier plots and the Cox proportional hazards model, where the censorship data occurred prior to the earliest events were dropped automatically by default of the SPSS Statistics 13.0 statistical software (SPSS Inc., Chicago, IL, USA). Statistical significance in the Cox proportional hazards model was evaluated using Wald tests. All tests were two-tailed. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Germline GALNT14 genotypes and tumor characteristics associated with overall survival in resected cholangiocarcinoma

Clinicopathological parameters of 112 patients with surgically resected cholangiocarcinoma are summarized in [Table I](#tI-ol-0-0-5991){ref-type="table"}. Major features of this cohort were as follows: HBsAg-negative (76.8%), anti-HCV-negative (86.6%), non-cirrhotic (83%), non-HCC-cholangiocarcinoma-mixed histology (87.5%) and intrahepatic (77.7%). The frequency of the *GALNT14*-rs9679162 genotypes 'TT', 'TG' and 'GG' were 31.3%, 49.1% and 19.6%, respectively ([Fig. 1A](#f1-ol-0-0-5991){ref-type="fig"}), which did not deviate significantly from the ethnic reference genotype distribution of the HapMap Chinese Han Beijing (CHB) and Metropolitan Denver (CHD) cohorts (Cochran-Armitage Trend test, P=0.59 and P=0.46, respectively) ([@b23-ol-0-0-5991]).

Subsequently, clinicopathological parameters and *GALNT14* genotypes were determined to be correlated with overall survival using the Cox proportional hazards model. In previous clinical studies, the genotype-prognosis association was revealed to be based on comparison of the 'TT' and 'non-TT' genotypes (including 'TG' and 'GG') ([@b12-ol-0-0-5991]--[@b14-ol-0-0-5991]); therefore, the same genotype classification was used in the current study. The median post-resection follow-up time was 14 months (range, 1--180). Age, sex, liver cirrhosis, cholangitis and biliary tree stones did not demonstrate significant associations with overall survival post-resection. By contrast, five tumor characteristics (vessel invasion, perineural invasion, lymph node metastasis, largest tumor size and resection margins), two tumor-associated serum biomarkers (CEA and CA-19-9 levels) and *GALNT14* genotypes, revealed significant associations in univariate analysis ([Table II](#tII-ol-0-0-5991){ref-type="table"}). Patients stratified by the 'TT' and 'non-TT' genotypes demonstrated distinguishable survival curves in the Kaplan-Meier plot (log-rank, P=0.023; [Fig. 1B](#f1-ol-0-0-5991){ref-type="fig"}). Subsequently, multivariate analysis was performed on these associated factors, excluding CEA and CA-19-9, which had not been assessed in the majority of patients. It was revealed that vascular and perineural invasions are two independent factors associated with overall survival (P=0.002 and P=0.001, respectively), whereas *GALNT14* genotypes were not independently associated with overall survival.

### Germline GALNT14 genotypes are independently correlated with perineural invasion and lymph node metastasis in resected cholangiocarcinoma

The genotype-prognosis association was exclusively observed in the univariate analysis, and not in the multivariate analysis, which suggested that the genotype may have an unrecognized association with the tumor characteristics. In consideration of this, the present study further investigated the correlations between genotypes and the evaluated clinicopathological parameters, using univariate and multivariate linear regressions. Amongst all the clinicopathological parameters, two tumor characteristics, perineural invasion and lymph node metastasis, were determined to be independently associated with the *GALNT14* genotype 'TT' (multivariate analysis, P=0.035 and P=0.005, respectively; [Table III](#tIII-ol-0-0-5991){ref-type="table"}). The percentage of perineural invasion was significantly higher in patients with the 'TT' genotype, compared with those with a 'non-TT' genotype (P=0.004; [Fig. 1C](#f1-ol-0-0-5991){ref-type="fig"}). Similarly, the frequency of lymph node metastasis was significantly higher in patients with the 'TT' genotype, compared with the 'non-TT' genotype (P=0.011; [Fig. 1C](#f1-ol-0-0-5991){ref-type="fig"}).

Subsequently, the genotype distributions ('TT' vs. 'non-TT') were investigated in subgroups of patients stratified by the presence or absence of the two aggressive characteristics, perineural invasion and lymph node metastasis. The distribution of patients with perineural invasion deviated significantly from the reference cohorts, HapMap-CHB and CHD (CHB, P=0.049; CHD, P=0.034), where the 'TT' type was particularly enriched ([@b23-ol-0-0-5991]). No such deviations were identified in patients without perineural invasion (CHB, P=0.144; CHD, P=0.236). Similarly, the genotype distribution in patients with lymph node metastasis also deviated significantly from the ethnic references (CHB, P=0.046; CHD, P=0.032). No such deviations were identified in patients without lymph node metastasis (CHB, P=0.337; CHD, P=0.501).

Discussion
==========

Aggressive growth of cholangiocarcinoma occurred sporadically with no known major predisposition etiology ([@b3-ol-0-0-5991],[@b4-ol-0-0-5991]). Therefore, it was conjectured in the present study that personal genetic background may contribute to onset, progression and malignant phenotypes. The present study demonstrated that the *GALNT14* genotype 'TT' was independently associated with two known predictors of unfavorable prognosis in cholangiocarcinoma: Perineural invasion and lymph node metastasis. The 'TT' genotypes were revealed to be particularly enriched in patients with these aggressive phenotypes, as compared with the ethnic references. Such enrichment may be due to patients with the 'TT' type being more likely to develop these two aggressive tumor characteristics. In the survival analysis, the association between the *GALNT14* genotype and overall survival was only observed in univariate analysis, and not in multivariate analysis. It is possible that the tumor characteristics-prognosis association in the multivariate analysis concealed the underlying genotype-prognosis association. As the genotype is determined at birth, while perineural invasion and lymph node metastasis are identified at the time of surgical treatment, a causal association may be inferred that the genotype first affected the development of these two tumor characteristics, which subsequently altered the postoperative prognosis ([Fig. 1](#f1-ol-0-0-5991){ref-type="fig"}).

The present study was an extension of previous studies on HCC and cholangiocarcinoma, as a result of their similarities and differences ([@b3-ol-0-0-5991],[@b15-ol-0-0-5991],[@b17-ol-0-0-5991],[@b18-ol-0-0-5991],[@b23-ol-0-0-5991],[@b24-ol-0-0-5991]). Cholangiocarcinoma arises from bile duct epithelial cells, whereas HCC originates from hepatocytes ([@b3-ol-0-0-5991],[@b24-ol-0-0-5991]). Cholangiocarcinoma and HCC have fundamental differences in their oncogenic pathways ([@b3-ol-0-0-5991],[@b24-ol-0-0-5991]). HCC is primarily caused by viral hepatitis, including chronic HBV rather than HCV, dependent on the region of the world ([@b25-ol-0-0-5991]). By contrast, even in Taiwan, which is a HBV hyperendemic region, the percentage of HBsAg-positivity among patients with cholangiocarcinoma is low (23.2%), as compared with in patients with HCC (\>60%) ([@b1-ol-0-0-5991],[@b2-ol-0-0-5991],[@b26-ol-0-0-5991]). An additional difference is that HCC often develops from a cirrhotic background; however, the majority of patients with cholangiocarcinoma in the present study were non-cirrhotic (83%) ([@b26-ol-0-0-5991]). Despite these differences, certain HCC and cholangiocarcinoma cases have overlapping histology patterns, demonstrating mixed tissue types ([@b3-ol-0-0-5991]). As *GALNT14* encodes an enzyme that catalyzes the O-glycosylation of numerous proteins, it is possible that differential O-glycosylation environments associated with various *GALNT14* genotypes may result in the distinct tumor characteristics of cholangiocarcinoma and HCC ([@b19-ol-0-0-5991]). Further studies focusing on the underlying molecular mechanisms are required to clarify this point.

In conclusion, patients with the *GALNT14* genotype 'TT' are associated with two aggressive tumor characteristics: Perineural invasion and lymph node metastasis. This genotype was therefore associated with an unfavorable overall survival.
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###### 

Clinical and tumor characteristics of the 112 patients included in the study.

  Parameters                                  Values
  ------------------------------------------- ------------------
  Age, years, mean ± SD                       60.2±10.7
  Sex, male (%)                               62 (55.4)
  HBsAg, positive (%)                         26 (23.2)
  Anti-HCV, positive (%)                      15 (13.4)
  Cirrhosis, positive (%)                     19 (17.0)
  ECOG stage                                  
    0                                         68 (60.7)
    1                                         44 (39.3)
  Biliary tree stones, yes (%)                24 (21.4)
  Stone-unrelated cholangitis, yes (%)        46 (41.0)
  Tumor characteristics                       
  Perihilar, yes (%)                          25 (22.3)
  Invasion to vessel, yes (%)                 30 (26.8)
  Perineural invasion, yes (%)                48 (42.9)
  Periductal invasion, yes (%)                45 (40.2)
  Lymph node involvement, yes (%)             33 (29.5)
  Tumor number                                
    1                                         101 (90.2)
    2                                         6
    3                                         1
    \>3                                       4
  Tumor size, cm, mean ± SD                   6.0±3.2
  Histology                                   
    Well differentiated, yes (%)              25 (22.3)
    Mixed hepatocellular carcinoma, yes (%)   14 (12.5)
  Extrahepatobiliary invasion, yes (%)        46 (41.1)
  Resection margin involvement, yes (%)       44 (39.3)
  More than one segment of resection,         98 (87.5)
  yes (%)                                     
  Biochemistry                                
    CEA, ng/ml, mean ± SD                     41.0±104.4
    CA-19-9, U/ml, mean ± SD                  8,648.5±26,889.6
    Bilirubin, mg/dl, mean ± SD               1.8±3.1
    AST, U/l, mean ± SD                       56.3±69.5
    ALT, U/l, mean ± SD                       62.9±83.4
  GALNT14 genotype                            
    TT (%)                                    35 (31.3)
    TG (%)                                    55 (49.1)
    GG (%)                                    22 (19.6)

HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SD, standard deviation.

###### 

Analysis of clinicopathological and genotypic parameters for overall survival in 112 patients with cholangiocarcinoma receiving surgery.

                                                                                 Univariate analysis                             Multivariate analysis                                                                                   
  ----------------------------------------------------------------------- ------ ----------------------------------------------- ------------------------ ------------------------------------------------------ ----------------------- ----------------------------------------------------
  Age (years)                                                                                                                                             0.732                                                                          
    ≤60                                                                     57   98.5 (69.4--127.4)                                                                                                                                      
    \>60                                                                    55   89.9 (68.6--111.6)                              1.138 (0.544--2.544)                                                                                    
  Sex                                                                                                                                                     0.964                                                                          
    Female                                                                  50   81.8 (57.3--106.3)                                                                                                                                      
    Male                                                                    62   108.6 (78.3--139.3)                             0.983 (0.472--2.472)                                                                                    
  HBsAg                                                                                                                                                   0.055                                                                          
    Negative                                                                86   73.2 (54.1--92.1)                                                                                                                                       
    Positive                                                                26   138.2 (103.3--173.3)                            0.346 (0.117--1.117)                                                                                    
  Anti-HCV                                                                                                                                                0.278                                                                          
    Negative                                                                97   95.2 (71.6--118.6)                                                                                                                                      
    Positive                                                                15   64.7 (51.1--78.1)                               0.450 (0.106--1.106)                                                                                    
  Cirrhosis                                                                                                                                               0.341                                                                          
    No                                                                      93   96.1 (72.1--120.1)                                                                                                                                      
    Yes                                                                     19   74.1 (54.7--93.7)                               0.558 (0.168--1.168)                                                                                    
  ECOG stage                                                                                                                                              0.062                                                                          
    0                                                                       68   109.5 (83.8--135.8)                                                                                                                                     
    \>0                                                                     44   37.7 (20.9--54.9)                               2.135 (0.964--4.964)                                                                                    
  Biliary tree stones                                                                                                                                     0.092                                                                          
    No                                                                      88   106.4 (81.9--130.9)                                                                                                                                     
    Yes                                                                     24   37.9 (13.1--62.1)                               2.130 (0.883--5.883)                                                                                    
  Cholangitis (stone-unrelated)                                                                                                                           0.081                                                                          
    No                                                                      66   76.1 (53.6--98.6)                                                                                                                                       
    Yes                                                                     46   118.6 (84.8--152.8)                             0.491 (0.221--1.221)                                                                                    
  Tumor characteristics Location                                                                                                                          0.157                                                                          
    Intrahepatic                                                            87   102.8 (74.9--130.9)                                                                                                                                     
    Perihilar                                                               25   68.2 (38.4--97.4)                               1.742 (0.808--3.808)                                                                                    
  Invasion to vessels                                                                                                                                     0.010^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                             0.002^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^
    No                                                                      82   109.2 (83.9--134.9)                                                                                                                                     
    Yes                                                                     30   39.8 (25.5--54.5)                               2.838 (1.285--6.285)                                                            3.853 (1.624--9.624)    
  Perineural invasion                                                                                                                                     \<0.001^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                           0.001^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^
    No                                                                      64   141.6 (115.0--168.0)                                                                                                                                    
    Yes                                                                     48   51.6 (29.8--73.8)                               4.812 (2.126--10.126)                                                           5.086 (1.894--13.894)   
  Periductal invasion                                                                                                                                     0.997                                                                          
    No                                                                      67   99.3 (71.2--127.2)                                                                                                                                      
    Yes                                                                     45   85.3 (59.5--111.5)                              1.002 (0.472--2.472)                                                                                    
  Lymph node involvement                                                                                                                                  \<0.001^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                           0.308
    No                                                                      79   119.3 (92.1--146.1)                                                                                                                                     
    Yes                                                                     33   45.5 (15.6--75.6)                               3.756 (1.796--7.796)                                                            1.645 (0.632--4.632)    
  Tumor number                                                                                                                                                                                                                           
    1                                                                     101    105.8 (82.1--129.1)                                                                                                                                     
    \>1                                                                     11   68.1 (27.9--108.9)                              1.361 (0.471--3.471)                                                                                    
  Largest tumor size (cm)                                                                                                                                 0.008^[a](#tfn3-ol-0-0-5991){ref-type="table-fn"}^                             0.113
    ≤5.25                                                                   56   116.5 (86.5--146.5)                                                                                                                                     
    \>5.25                                                                  56   69.0 (38.8--99.8)                               2.839 (1.306--6.306)                                                            2.147 (0.835--5.835)    
  Histology                                                                                                                                               0.654                                                                          
    Well differentiated                                                     25   65.0 (49.0--81.0)                                                                                                                                       
    Moderate/poorly differentiated                                          87   96.3 (71.5--121.5)                              1.249 (0.472--3.472)                                                                                    
  Mixed hepatocellular carcinoma                                                                                                                          0.126                                                                          
    No                                                                      98   85.1 (64.1--106.1)                                                                                                                                      
    Yes                                                                     14                                                   0.037 (0.001--2.001)                                                                                    
  Extrahepatobiliary invasion                                                    ^[b](#tfn4-ol-0-0-5991){ref-type="table-fn"}^                            0.268                                                                          
    No                                                                      66   102.3 (75.5--129.5)                                                                                                                                     
    Yes                                                                     46   85.9 (59.9--111.9)                              1.532 (0.720--3.720)                                                                                    
  Resection margin                                                                                                                                        0.015^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                             0.180
    R0                                                                      68   113.3 (87.4--139.4)                                                                                                                                     
    R1                                                                      44   37.8 (26.1--49.1)                               2.654 (1.207--5.207)                                                            1.736 (0.776--3.776)    
  Resection method                                                                                                                                        0.993                                                                          
    Mono-segmental                                                          14   58.1 (33.8--82.8)                                                                                                                                       
    \>1 segment                                                             98   101.7 (77.6--125.6)                             1.005 (0.346--2.346)                                                                                    
  Biochemistry CEA (ng/ml)^[a](#tfn3-ol-0-0-5991){ref-type="table-fn"}^                                                                                   \<0.001^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                           
    ≤5.1                                                                    36   133.8 (102.5--165.5)                                                                                                                                    
    \>5.1                                                                   33   47.6 (20.6--74.6)                               6.069 (2.332--15.332)                                                                                   
  CA-19-9 (U/ml)^[a](#tfn3-ol-0-0-5991){ref-type="table-fn"}^                                                                                             \<0.001^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                           
    ≤107                                                                    41   139.4 (111.0--167.0)                                                                                                                                    
    \>107                                                                   29   29.7 (15.8--43.8)                               14.531 (4.195--50.195)                                                                                  
  Bilirubin (mg/dl)                                                                                                                                       0.371                                                                          
    ≤0.9                                                                    59   97.2 (71.5--123.5)                                                                                                                                      
    \>0.9                                                                   53   100.1 (67.3--133.3)                             1.396 (0.642--2.642)                                                                                    
  AST (U/l)                                                                                                                                               0.356                                                                          
    ≤31.5                                                                   56   103.0 (73.6--132.6)                                                                                                                                     
    \>31.5                                                                  56   92.2 (62.8--121.8)                              1.415 (0.677--2.677)                                                                                    
  ALT (U/l)                                                                                                                                               0.087                                                                          
    ≤32.0                                                                   58   115.6 (84.7--146.7)                                                                                                                                     
    \>32.0                                                                  54   79.7 (51.6--107.6)                              1.926 (0.908--4.908)                                                                                    
  Chemotherapy                                                                                                                                            0.577                                                                          
    No                                                                      72   15.6 (2.2--29.2)                                                                                                                                        
    Yes                                                                     40   33.2 (6.7--59.7)                                0.807 (0.380--1.380)                                                                                    
  *GALNT14* genotype                                                                                                                                      0.027^[c](#tfn5-ol-0-0-5991){ref-type="table-fn"}^                             0.897
    Non-TT                                                                  77   113.6 (86.0--141.0)                                                                                                                                     
    TT                                                                      35   71.6 (39.1--104.1)                              2.282 (1.098--4.098)                                                            0.948 (0.424--2.424)    

CI, confidence interval; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Missing data noted

All survived during follow-ups

P\<0.05.

###### 

Linear regression analysis for correlation between clinicopathological factors and the *GALNT14* 'TT' genotype.

                                     Univariate analysis   Multivariate analysis                                     
  ---------------------------------- --------------------- ----------------------- ---------- ------- -------------- ----------
  Sex, male                          0.059                 −0.117--0.117           0.510                             
  Age, years                         −0.003                −0.011--0.011           0.438                             
  HBsAg-positive                     −0.006                −0.214--0.214           0.952                             
  Anti-HCV-positive                  −0.053                −0.310--0.310           0.684                             
  ECOG status                        −0.103                −0.281--0.281           0.255                             
  Cirrhosis                          0.067                 −0.166--0.166           0.568                             
  Biliary tree stones                0.080                 −0.133--0.133           0.461                             
  Cholangitis (stone-unrelated)      0.068                 −0.112--0.112           0.456                             
  Tumor characteristics                                                                                              
    Perihilar                        0.113                 −0.097--0.097           0.288                             
    Invasion to vessels              0.120                 −0.077--0.077           0.231                             
    Perineural invasion              0.255                 0.085--0.085            0.004^a^   0.185   0.014--0.014   0.035^a^
    Periductal invasion              −0.002                −0.181--0.181           0.979                             
    Lymph node involvement           0.060                 0.027--0.027            0.001^a^   0.050   0.015--0.015   0.005^a^
    Tumor number \>1                 0.158                 −0.135--0.135           0.289                             
    Tumor size (cm)                  0.013                 −0.014--0.014           0.339                             
    Moderate/poor differentiation    −0.113                −0.322--0.322           0.288                             
    Mixed hepatocellular carcinoma   −0.031                −0.295--0.295           0.819                             
    Extrahepatobiliary invasion      0.134                 −0.042--0.042           0.135                             
    Resection margin involved        0.009                 −0.170--0.170           0.918                             
    \>1 segment of resection         0.031                 −0.234--0.234           0.819                             
  Biochemistry                                                                                                       
    CEA, ng/ml                       0.001                 0.000--0.000            0.050                             
    CA-19-9, ×1,000 U/ml             0.004                 −0.001--0.001           0.103                             
    Bilirubin, mg/dl                 0.002                 −0.026--0.026           0.870                             
    AST, U/l                                 −0.00000257   −0.001--0.001           0.997                             
    ALT, U/l                         0.000                 −0.001--0.001           0.667                             

CI, confidence interval; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase; *GALNT14*, N-acetylgalactosaminyltransferase 14.

[^1]: Contributed equally
